Loading clinical trials...
Loading clinical trials...
An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus", With the Participation of Adolescent Volunteers
Conditions
Interventions
Gam-COVID-vac M
Placebo
Locations
2
Russia
Children's City Clinical Hospital named after Z.A. Bashlyaeva of the Moscow Department of Health
Moscow, Russia
Morozovskaya Children's City Clinical Hospital of the Moscow Department of Health
Moscow, Russia
Start Date
July 5, 2021
Primary Completion Date
November 6, 2022
Completion Date
December 31, 2023
Last Updated
September 16, 2021
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions